Fulcrum Therapeutics

PriceFulcrum Therapeutics

FULC

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Historical stock price chart and annual return over the past years

-76%

5 years

% Total

FULC
-25%

5 years

Annual Return

FULC